Enter Puma Biotech, which is paying a modest $7 million ... It is also working on PB357, an ERBB 2 receptor antagonist licensed from Pfizer, but that is still in preclinical development, so ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback